Patents by Inventor Kenneth J. Widder
Kenneth J. Widder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240139166Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition comprises a low concentration of an ophthalmic agent for treatment of presbyopia. Further disclosed herein is an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water.Type: ApplicationFiled: February 3, 2022Publication date: May 2, 2024Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
-
Patent number: 11912545Abstract: A wireless hoist system including a first hoist device having a first motor and a first wireless transceiver and a second hoist device having a second motor and a second wireless transceiver. The wireless hoist system includes a controller in wireless communication with the first wireless transceiver and the second wireless. The controller is configured to receive a user input and determine a first operation parameter and a second operation parameter based on the user input. The controller is also configured to provide, wirelessly, a first control signal indicative of the first operation parameter to the first hoist device and provide, wirelessly, a second control signal indicative of the second operation parameter to the second hoist device. The first hoist device operates based on the first control signal and the second hoist device operates based on the second control signal.Type: GrantFiled: June 26, 2020Date of Patent: February 27, 2024Assignee: Milwaukee Electric Tool CorporationInventors: Matthew Post, Gareth Mueckl, Matthew N. Thurin, Joshua D. Widder, Timothy J. Bartlett, Patrick D. Gallagher, Jarrod P. Kotes, Karly M. Schober, Kenneth W. Wolf, Terry L. Timmons, Mallory L. Marksteiner, Jonathan L. Lambert, Ryan A. Spiering, Jeremy R. Ebner, Benjamin A. Smith, James Wekwert, Brandon L. Yahr, Troy C. Thorson, Connor P. Sprague, John E. Koller, Evan M. Glanzer, John S. Scott, William F. Chapman, III, Timothy R. Obermann
-
Patent number: 11896588Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, Wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: November 16, 2022Date of Patent: February 13, 2024Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
-
Patent number: 11890277Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: November 16, 2022Date of Patent: February 6, 2024Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
-
Patent number: 11883390Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: November 16, 2022Date of Patent: January 30, 2024Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
-
Publication number: 20230381016Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of a muscarinic antagonist or an ophthalmic agent for treatment of an ophthalmic disorder or condition in a preservative-free ophthalmic formulation. Further disclosed herein include an ophthalmic composition including a low concentration of a muscarinic antagonist or an ophthalmic agent and deuterated water. Also disclosed herein are methods of treating an ophthalmic condition or disease by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: August 1, 2023Publication date: November 30, 2023Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
-
Publication number: 20230092957Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: November 16, 2022Publication date: March 23, 2023Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
-
Publication number: 20230093205Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: November 16, 2022Publication date: March 23, 2023Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
-
Publication number: 20230091109Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, Wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: November 16, 2022Publication date: March 23, 2023Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
-
Patent number: 11596625Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: November 13, 2020Date of Patent: March 7, 2023Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
-
Publication number: 20230041788Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition. Further disclosed herein is an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Further disclosed herein is an ophthalmic including a low concentration of an ophthalmic agent and various ratios of water to deuterated water.Type: ApplicationFiled: December 15, 2020Publication date: February 9, 2023Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
-
Publication number: 20220409605Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: August 24, 2022Publication date: December 29, 2022Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
-
Publication number: 20220409603Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: August 24, 2022Publication date: December 29, 2022Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
-
Publication number: 20220409604Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: August 24, 2022Publication date: December 29, 2022Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
-
Publication number: 20220378775Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: February 25, 2022Publication date: December 1, 2022Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
-
Publication number: 20220265631Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: April 15, 2022Publication date: August 25, 2022Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
-
Publication number: 20220265632Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: April 15, 2022Publication date: August 25, 2022Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER, Harun TAKRURI
-
Patent number: 11382909Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: GrantFiled: November 7, 2019Date of Patent: July 12, 2022Assignee: SYDNEXIS, INC.Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri
-
Publication number: 20210393649Abstract: Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: June 1, 2021Publication date: December 23, 2021Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER
-
Publication number: 20210283142Abstract: Provided herein is an ophthalmic composition formulated in deuterated water. Also disclosed herein are methods of treating, ameliorating, or reducing ophthalmic conditions or diseases by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.Type: ApplicationFiled: June 1, 2021Publication date: September 16, 2021Inventors: Gregory I. OSTROW, Kenneth J. WIDDER, David S. BAKER